Sign in
CompletedPhase 3

TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France20 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
192 people enrolled
Started
24 Mar 2019
Ended
4 Mar 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Liberal Red blood cell transfusion
  • Restrictive Red blood cell transfusion
Record updated
25 June 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Age > 18 years
  • Evolutive (complete remission < 2 years) malignant solid tumor or chronic or acute hematological malignancy
  • Septic shock defined as:
  • Presumed or documented infection
  • Acute circulatory failure defined as hypotension requirement of vasoactive drugs for more than one hour (norepinephrine or epinephrine ≥ 0.1 µg/kg/min)
  • Tissue hypoxia defined by arterial lactate level > 2 mmol/L within 3 hours prior to inclusion
  • Hemoglobin level < 9 g/dL
  • Informed consent from patients or surrogates

Who cannot take part

  • Acute life-threatening bleeding
  • Ongoing acute coronary syndrome or any other acute ischemic condition
  • End-of-life decisions at the time of ICU admission
  • Refusal of transfusions for personal beliefs
  • Lack of social security coverage
  • Pregnancy or breastfeeding

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Septic shock is a frequent complication associated with high mortality in patients with malignancies. The best transfusion strategy (restrictive or liberal) for the resuscitation of septic shock remains a controversial issue, in relation with potentially discrepant goals of tissue oxygenation and transfusion sparing.

Read full original descriptionShow less

In this study, the investigators propose to address the efficacy of two RBC transfusion strategies (liberal or restrictive) in restoring appropriate tissue oxygenation as well as their tolerance.

The investigators designed a prospective randomized multicenter trial aimed at comparing liberal and restrictive RBC transfusion strategies applied during the first 48 hours of resuscitation in cancer patients with septic shock and anemia.

The 2 groups in the trial

  • Liberal strategyExisting treatment, for comparison

    Maintain a hemoglobin level \> 9 g/dL during the first 48 hours of resuscitation of septic shock

    Treatment: Liberal Red blood cell transfusion

  • Restrictive strategyTreatment being tested

    Maintain a hemoglobin level \> 7 g/dL during the resuscitation of septic shock

    Treatment: Restrictive Red blood cell transfusion

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Stratégie Transfusionnelle érythrocytaire Dans la réanimation du Choc Septique du Patient d'Onco-hématologie : Essai randomisé Multicentrique TRANSPORT [TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock]
Publications
Record updated
25 June 2024